A Kit Formulated Under Good Manufacturing Practices for Labeling Human Epidermal Growth Factor with 111In for Radiotherapeutic Applications

Journal of Nuclear Medicine

Judy Wang¹  Katherine A. Vallis¹  Paul Chen¹  Deborah A. Scollard¹  Lee A. Henderson¹  Barry M. Bowen¹  Hridya Mondal¹  Raymond M. Reilly¹ 

关键词: Auger electrons;    ¹¹¹In;    epidermal growth factor;    kit;    good manufacturing practices;   

DOI  :  

学科分类：医学（综合）

来源: Society of Nuclear Medicine

【 摘 要 】

Our goal was to design and manufacture a kit under good manufacturing practices (GMP) for the preparation of 111In-DTPA-hEGF Injection, a novel targeted radiotherapeutic agent for advanced epidermal growth factor receptor (EGFR)-positive breast cancer. Methods: Human EGF (hEGF) was derivatized with diethylenetriaminepentaacetic acid (DTPA) and then purified by size-exclusion chromatography and ultrafiltration. Kits were prepared by dispensing 0.25 mg (1 mL) of DTPA-hEGF in 1 mol/L sodium acetate buffer [pH 6.0] into single-dose glass vials. Raw materials were pharmacopoieal or reagent grade according to the American Chemical Society and were tested for identity and purity. Kits were tested for protein concentration, purity and homogeneity (sodium dodecyl sulfate polyacrylamide gel electrophoresis and size-exclusion high-performance liquid chromatography), pH, clarity and color, volume, DTPA substitution, labeling efficiency, receptor binding to MDA-MB-468 human breast cancer cells, and sterility and apyrogenicity. 111In-DTPA-hEGF Injection was tested for pH, radionuclidic and radiochemical purity, clarity and color, and sterility and apyrogenicity. Results: Four lots of kits and 8 lots of 111In-DTPA-hEGF Injection passed all quality specifications. The labeling efficiency was 94%–99% with 115–773 MBq 111In chloride added to a single kit. 111In-DTPA-hEGF exhibited preserved receptor binding against MDA-MB-468 cells (affinity constant [Ka], 0.9–1.1 × 107 L/mol; maximum number of binding sites per cell [Bmax], 1.1–2.2 × 106 sites per cell). In addition, labeling of aliquots of the kit suggested that a single vial could be labeled with up to 3,083 MBq 111In while maintaining a radiochemical purity of >90%. Kits were stable for >90 d and 111In-DTPA-hEGF Injection was stable for >24 h stored at 4°C. Conclusion: The kit formulation is suitable for preparing 111In-DTPA-hEGF Injection for a phase I clinical trial in patients with advanced EGFR-positive breast cancer. Establishment of the GMP processes for 111In-DTPA-hEGF Injection provides a useful example of manufacturing biotechnology-based investigational radiopharmaceuticals in an academic environment for early phase I clinical trials.

【 授权许可】

Unknown